Alimentary pharmacology & therapeutics
-
Aliment. Pharmacol. Ther. · Jun 2004
Randomized Controlled Trial Clinical TrialInfluence of a lipase inhibitor on gastric sensitivity and accommodation to an orally ingested meal.
Intraduodenal administration of lipids, through lipid digestion and release of cholecystokinin (CCK), induces viscero-visceral reflexes that affect gastric tone and sensitivity. It is unclear whether the same mechanisms control gastric function after an orally ingested meal. ⋯ Administration of a lipase inhibitor does not affect gastric compliance, sensitivity to distension and accommodation to an orally ingested meal, and does not influence meal-induced satiety.
-
Aliment. Pharmacol. Ther. · Jun 2004
Comparative Study Clinical Trial Controlled Clinical TrialComparison of transarterial chemoembolization and percutaneous acetic acid injection as the primary loco-regional therapy for unresectable hepatocellular carcinoma: a prospective survey.
Transarterial chemoembolization (TACE) and percutaneous acetic acid injection (PAI) are effective loco-regional therapies for hepatocellular carcinoma (HCC). ⋯ Patients with large HCC undergoing TACE tend to have a more favourable long-term outcome. For small HCC, either TACE or PAI therapy could be recommended as the primary treatment modality.
-
Aliment. Pharmacol. Ther. · Jun 2004
The length of newly diagnosed Barrett's oesophagus and prior use of acid suppressive therapy.
The length of Barrett's oesophagus seems to correlate well with indicators of severe gastro-oesophageal reflux disease. However, it remains unknown whether prior acid suppressive therapy affects the length of newly diagnosed Barrett's oesophagus. ⋯ The use of acid suppressive therapy among patients is associated with a reduction in the eventual length of newly diagnosed Barrett's oesophagus with gastro-oesophageal reflux disease. This finding is independent of the year of diagnosis or demographic features of patients. Further studies are required to confirm this finding.